about
Biosimilars for the Treatment of Cancer: A Systematic Review of Published EvidenceEstimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.Emerging data on improving response to hormone therapy: the role of novel targeted agents.Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.Biosimilar monoclonal antibodies (mAbs) in oncology.Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin AmericaIntegrating Biosimilars Into Oncology Practice: Implications for the Advanced PractitionerThe role of biosimilars in value-based oncology careComparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
P2860
Q36247037-03B66678-D53B-467A-832C-EA24F47D2376Q37598156-4238DBB5-0949-4647-840C-763FA7F79D89Q38643555-061AEDD1-0CA6-4E90-9452-1AB605324E23Q38686393-C9682158-62A9-4679-8C28-795466A875BCQ46537162-82419A62-D054-4809-9878-ECCCA8615376Q47706731-557E9450-54EB-4BB1-94C5-00C503F004F6Q47796704-656A9FC7-5824-4F38-BBD4-AB1AD029DB1FQ50207250-AC1F3B0A-68AF-472A-B080-3AD9509A0953Q55111318-F5EC293C-35BE-47BF-8C6F-922ABAE345A2Q57173064-A0077470-9198-481E-8986-1A8F8BE20E7EQ58585594-FF288A84-5ACE-4933-82F4-4DA9FC9E5876Q58605622-20252D9A-C1B2-4FEA-9337-8546A74E4F47Q58767252-E2C91BA7-9FA7-4079-914C-B1FA08C96AC4
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A clinician's guide to biosimilars in oncology
@ast
A clinician's guide to biosimilars in oncology
@en
A clinician's guide to biosimilars in oncology
@nl
type
label
A clinician's guide to biosimilars in oncology
@ast
A clinician's guide to biosimilars in oncology
@en
A clinician's guide to biosimilars in oncology
@nl
prefLabel
A clinician's guide to biosimilars in oncology
@ast
A clinician's guide to biosimilars in oncology
@en
A clinician's guide to biosimilars in oncology
@nl
P2093
P1476
A clinician's guide to biosimilars in oncology
@en
P2093
Hope S Rugo
Ira Jacobs
Julie A Rosenberg
Paul Cervi
P356
10.1016/J.CTRV.2016.04.003
P407
P50
P577
2016-04-21T00:00:00Z